한글목차

세계 사이토카인 시장은 2024년 952억 3,000만 달러로 평가되며, 2030년까지 CAGR 7.82%로 성장하여 새로운 최고치를 기록할 것으로 예상됩니다. 사이토카인은 면역체계 조절, 염증, 세포 간 의사소통에 관여하는 주요 신호전달 단백질로, 치료법 혁신과 질병 관리 모두에서 매우 중요한 역할을 하고 있습니다.

사이토카인의 생물학이 지속적으로 발전함에 따라 암, 자가면역질환, 감염성 질환 등에 대한 새로운 임상적 응용이 기대되고 있습니다. 전 세계적으로 만성질환의 급증은 사이토카인 기반 치료법의 개발과 보급을 촉진하여 시장을 지속적으로 성장시키고 있습니다.

연구개발 투자 확대와 정밀의료에 대한 노력에 힘입은 치료 혁신으로 사이토카인 치료는 현대 치료 프로토콜의 필수적인 요소로 변모하고 있습니다. 생물학적 제제 및 맞춤형 헬스케어 솔루션에 대한 의존도가 높아지면서 바이오의약품 및 바이오테크놀러지 산업 전반의 제품 개발에 더욱 박차를 가하고 있습니다. 임상 사용의 확대와 업계의 관심 증가로 인해 사이토카인 시장은 향후 몇 년 동안 역동적으로 발전할 준비가 되어 있습니다.

주요 시장 촉진요인

연구개발(R&D)의 전략적 중요성

2023년 미국 바이오제약 기업들은 연구개발에 약 960억 달러를 투자하여 혁신에 대한 업계의 의지를 보여주었습니다. 이러한 집중적인 노력은 다음과 같은 결과를 가져왔다:

안전성 및 유효성 프로파일을 개선한 획기적인 사이토카인 치료법 개발

차별화된 솔루션을 제공하는 기업의 경쟁력 강화

투자자 및 전략적 제휴사들의 관심 증가

보다 광범위한 임상적 사용으로 시장 잠재력 확대

주요 시장 과제

안전성 및 부작용

안전과 관련된 주요 이슈는 다음과 같습니다:

안전한 용량 및 치료 매개 변수를 확립하기 위한 장기 임상시험.

치료 채택 및 환자 신뢰에 영향을 미치는 부작용 위험성

규제 당국의 감시 강화, 승인 지연 및 컴플라이언스 부담 증가 가능성

이러한 우려를 해소하기 위해 기업들은 다음과 같은 투자를 하고 있습니다:

전임상 모델 및 고급 in vitro 테스트

임상시험 중 종합적인 안전성 모니터링

표적을 강화하고 부작용을 최소화하기 위한 분자 메커니즘에 대한 지속적인 연구.

주요 시장 동향

맞춤형 사이토카인 치료의 등장

사이토카인 치료를 둘러싼 환경은 맞춤형 의료로의 뚜렷한 변화를 목격하고 있습니다. 바이오마커와 유전자 프로파일링을 활용하여 맞춤형 사이토카인 치료는 다음과 같은 이점을 제공합니다:

표적화된 개입을 통한 치료 결과 개선

환자별 투여 전략을 통한 부작용 감소

주류 치료 요법에서 생물학적 제제 수용 촉진

목차

제1장 제품 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 사이토카인 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 사이토카인 유형별(종양괴사인자-TNF, 인터류킨-II, 인터페론-IFN, 상피성장인자-EGF, 기타)
  • 치료 용도별(암, 천식·기도 염증, 관절염, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 사이토카인 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 사이토카인 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 사이토카인 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 사이토카인 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 사이토카인 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병

제13장 세계의 사이토카인 시장 : SWOT 분석

제14장 경쟁 구도

• GlaxoSmithkline PLC
• Novartis AG
• Amgen Inc
• Pfizer Inc.
• Sanofi SA
• AstraZeneca plc
• Biocon Limited
• Abbvie Inc
• Johnson and Johnson
• UCB S.A

제15장 전략적 제안

제16장 조사 회사 소개 및 면책사항

영문목차

The Global Cytokine Market was valued at USD 95.23 billion in 2024 and is expected to witness significant expansion, reaching new heights by 2030 with a projected CAGR of 7.82%. Cytokines-key signaling proteins involved in immune system regulation, inflammation, and intercellular communication-have become pivotal in both therapeutic innovation and disease management.

Ongoing advancements in cytokine biology are unlocking novel clinical applications across cancer, autoimmune, and infectious diseases. The surge in chronic illness prevalence globally has driven the development and uptake of cytokine-based therapies, positioning the market for sustained growth.

Therapeutic innovations, supported by growing R&D investments and precision medicine initiatives, are transforming cytokine therapies into integral components of modern treatment protocols. Increasing reliance on biologics and personalized healthcare solutions is further fueling product development across biopharmaceutical and biotechnology industries. With expanding clinical use and heightened industry focus, the cytokine market is poised for dynamic evolution in the years ahead.

Key Market Drivers

Strategic Importance of Research and Development (R&D)

R&D remains a fundamental catalyst for growth in the cytokine market. As the biological complexity of cytokines becomes better understood, new opportunities for drug development and therapeutic application continue to emerge.

In 2023, U.S. biopharmaceutical firms invested nearly USD 96 billion in R&D, underlining the industry's commitment to innovation. This focus has led to:

Development of breakthrough cytokine therapies with improved safety and efficacy profiles

Strengthened competitive positioning for companies offering differentiated solutions

Heightened interest from investors and strategic collaborators

Broader clinical use, thereby expanding the market potential

Robust R&D pipelines, along with strategic collaborations between research institutions and industry stakeholders, are expected to further accelerate the development of targeted cytokine therapies.

Key Market Challenges

Safety and Adverse Effects

The therapeutic use of cytokines presents inherent challenges due to their potent biological activity. While effective, cytokines can produce complex and, at times, unpredictable physiological responses.

Major safety-related issues include:

Prolonged clinical trials to establish safe dosing and treatment parameters

Risk of adverse effects that may affect treatment adoption and patient trust

Heightened regulatory oversight, which may delay approvals and increase compliance burdens

To address these concerns, companies are investing in:

Preclinical models and advanced in vitro studies

Comprehensive safety monitoring during clinical trials

Continued research into molecular mechanisms to enhance targeting and minimize side effects

Key Market Trends

Emergence of Personalized Cytokine Therapies

The cytokine therapy landscape is witnessing a notable shift toward personalized medicine. By leveraging biomarkers and genetic profiling, personalized cytokine treatments offer:

Improved therapeutic outcomes through targeted intervention

Reduced adverse effects via patient-specific dosing strategies

Enhanced acceptance of biologics in mainstream treatment regimens

Pharmaceutical developers are increasingly investing in companion diagnostics, biomarker discovery, and niche formulations to align with this trend. These developments are reshaping therapeutic strategies and enabling a patient-centric approach, which is expected to be a significant market differentiator moving forward.

Key Market Players

• GlaxoSmithKline PLC
• Novartis AG
• Amgen Inc
• Pfizer Inc.
• Sanofi SA
• AstraZeneca plc
• Biocon Limited
• Abbvie Inc
• Johnson and Johnson
• UCB S.A

Report Scope:

In this report, the Global Cytokine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cytokine Market, By Cytokine Type:

• Tumour Necrosis Factor-TNF
• Interleukins-Il
• Interferons-IFN
• Epidermal Growth Factor-EGF
• Other

Cytokine Market, By Therapeutics Application:

• Cancer
• Asthma and Airway Inflammation
• Arthritis
• Other

Cytokine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cytokine Market.

Available Customizations:

Global Cytokine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cytokine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cytokine Type (Tumour Necrosis Factor-TNF, Interleukins-Il, Interferons-IFN, Epidermal Growth Factor-EGF, Other)
  • 5.2.2. By Therapeutics Application (Cancer, Asthma and Airway Inflammation, Arthritis, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Cytokine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cytokine Type
  • 6.2.2. By Therapeutics Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cytokine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cytokine Type
      • 6.3.1.2.2. By Therapeutics Application
  • 6.3.2. Canada Cytokine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cytokine Type
      • 6.3.2.2.2. By Therapeutics Application
  • 6.3.3. Mexico Cytokine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cytokine Type
      • 6.3.3.2.2. By Therapeutics Application

7. Europe Cytokine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cytokine Type
  • 7.2.2. By Therapeutics Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cytokine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cytokine Type
      • 7.3.1.2.2. By Therapeutics Application
  • 7.3.2. United Kingdom Cytokine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cytokine Type
      • 7.3.2.2.2. By Therapeutics Application
  • 7.3.3. Italy Cytokine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Cytokine Type
      • 7.3.3.2.2. By Therapeutics Application
  • 7.3.4. France Cytokine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cytokine Type
      • 7.3.4.2.2. By Therapeutics Application
  • 7.3.5. Spain Cytokine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cytokine Type
      • 7.3.5.2.2. By Therapeutics Application

8. Asia-Pacific Cytokine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cytokine Type
  • 8.2.2. By Therapeutics Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Cytokine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cytokine Type
      • 8.3.1.2.2. By Therapeutics Application
  • 8.3.2. India Cytokine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cytokine Type
      • 8.3.2.2.2. By Therapeutics Application
  • 8.3.3. Japan Cytokine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cytokine Type
      • 8.3.3.2.2. By Therapeutics Application
  • 8.3.4. South Korea Cytokine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cytokine Type
      • 8.3.4.2.2. By Therapeutics Application
  • 8.3.5. Australia Cytokine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cytokine Type
      • 8.3.5.2.2. By Therapeutics Application

9. South America Cytokine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cytokine Type
  • 9.2.2. By Therapeutics Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cytokine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cytokine Type
      • 9.3.1.2.2. By Therapeutics Application
  • 9.3.2. Argentina Cytokine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cytokine Type
      • 9.3.2.2.2. By Therapeutics Application
  • 9.3.3. Colombia Cytokine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cytokine Type
      • 9.3.3.2.2. By Therapeutics Application

10. Middle East and Africa Cytokine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cytokine Type
  • 10.2.2. By Therapeutics Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cytokine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cytokine Type
      • 10.3.1.2.2. By Therapeutics Application
  • 10.3.2. Saudi Arabia Cytokine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cytokine Type
      • 10.3.2.2.2. By Therapeutics Application
  • 10.3.3. UAE Cytokine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cytokine Type
      • 10.3.3.2.2. By Therapeutics Application

11. Market Dynamics

• 11.1. Driver
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Cytokine Market: SWOT Analysis

14. Competitive Landscape

• 14.1. GlaxoSmithkline PLC
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Novartis AG
• 14.3. Amgen Inc
• 14.4. Pfizer Inc.
• 14.5. Sanofi SA
• 14.6. AstraZeneca plc
• 14.7. Biocon Limited
• 14.8. Abbvie Inc
• 14.9. Johnson and Johnson
• 14.10. UCB S.A

15. Strategic Recommendations

16. About Us & Disclaimer